

PART 514—NEW ANIMAL DRUG APPLICATIONS

Subpart A—General Provisions

Sec.

- 514.1 Applications.
- 514.2 Applications for animal feeds bearing or containing new animal drugs.
- 514.6 Amended applications.
- 514.7 Withdrawal of applications without prejudice.
- 514.8 Supplemental new animal drug applications.
- 514.9 Supplemental applications for animal feeds bearing or containing new animal drugs.
- 514.10 Confidentiality of data and information in an investigational new animal drug notice and a new animal drug application file for an antibiotic drug.
- 514.11 Confidentiality of data and information in a new animal drug application file.
- 514.12 Confidentiality of data and information in an investigational new animal drug notice.
- 514.15 Untrue statements in applications.

Subpart B—Administrative Actions on Applications

- 514.100 Evaluation and comment on applications.
- 514.105 Approval of applications.
- 514.106 Approval of supplemental applications.
- 514.110 Reasons for refusing to file applications.
- 514.111 Refusal to approve an application.
- 514.112 Return of applications for animal feeds bearing or containing new animal drugs.
- 514.115 Withdrawal of approval of applications.
- 514.116 Notice of withdrawal of approval of application.
- 514.120 Revocation of order refusing to approve an application or suspending or withdrawing approval of an application.
- 514.121 Service of notices and orders.

Subpart C—Hearing Procedures

- 514.200 Contents of notice of opportunity for a hearing.
- 514.201 Procedure for hearings.

Subparts D–E [Reserved]

Subpart F—Judicial Review

- 514.235 Judicial review.

AUTHORITY: Secs. 501, 502, 512, 701, 721, 801 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351, 352, 360b, 371, 379e, 381).

SOURCE: 40 FR 13825, Mar. 27, 1975, unless otherwise noted.

Subpart A—General Provisions

§ 514.1 Applications.

(a) Applications to be filed under section 512(b) of the act shall be submitted in the form described in paragraph (b) of this section. If any part of the application is in a foreign language, an accurate and complete English translation shall be appended to such part. Translations of literature printed in a foreign language shall be accompanied by copies of the original publication. The application must be signed by the applicant or by an authorized attorney, agent, or official. If the applicant or such authorized representative does not reside or have a place of business within the United States, the application must also furnish the name and post office address of, and must be countersigned by, an authorized attorney, agent, or official residing or maintaining a place of business within the United States. Pertinent information may be incorporated in, and will be considered as part of, an application on the basis of specific reference to such information, including information submitted under the provisions of § 511.1 of this chapter, in the files of the Food and Drug Administration; however, the reference must be specific in identifying the information. Any reference to information furnished by a person other than the applicant may not be considered unless its use is authorized in a written statement signed by the person who submitted it.

(b) Applications for new animal drugs shall be submitted in triplicate and assembled in the manner prescribed by paragraph (b)(15) of this section, and shall include the following information:

(1) *Identification.* Whether the submission is an original or supplemental application; the name and the address of the applicant; the date of the application; the trade name(s) (if one has been proposed) and chemical name(s) of the new animal drug. Upon receipt, the application will be assigned a number NADA ———, which shall be used for all correspondence with respect to the application.